Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
895
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2025-09-16
Important Milestone | IMM2510 (VEGF×PD-L1) Two Phase III Registration Clinical Trials Have Submitted EOP2 Innovative Therapy Enters Key Stage
More
2025-09-09
IMM2510 Shows Breakthrough Potential in IO-Resistant Squamous NSCLC at WCLC 2025
More
2025-08-28
Milestone Payment of $5 Million Received for IMM2510 and IMM27M Collaboration between ImmuneOnco and Instil Bio
More

For more information

Please follow the official wechat public account